PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | – | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | – | $2 |
| Gross Profit | -$0 | $0 | – | -$2 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $3 | – | -$0 |
| G&A Expenses | $0 | $3 | – | $1 |
| SG&A Expenses | $5 | $3 | – | $1 |
| Sales & Mktg Exp. | $0 | $0 | – | $0 |
| Other Operating Expenses | $0 | $0 | – | $0 |
| Operating Expenses | $12 | $6 | – | -$3 |
| Operating Income | -$12 | -$6 | – | $3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | – | -$0 |
| Pre-Tax Income | -$12 | -$6 | – | $3 |
| Tax Expense | -$1 | $0 | – | -$3 |
| Net Income | -$11 | -$6 | – | $6 |
| % Margin | – | – | – | – |
| EPS | -1.72 | 0 | – | 0.19 |
| % Growth | – | – | – | – |
| EPS Diluted | -1.72 | 0 | – | 0.19 |
| Weighted Avg Shares Out | 7 | 0 | – | 31 |
| Weighted Avg Shares Out Dil | 7 | 0 | – | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | – | $0 |
| Interest Expense | $0 | $0 | – | $0 |
| Depreciation & Amortization | $0 | $0 | – | $2 |
| EBITDA | -$12 | -$5 | – | -$6 |
| % Margin | – | – | – | – |